Human medicines European public assessment report (EPAR): Duvyzat, givinostat, Date of authorisation: 06/06/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Altuvoct, efanesoctocog alfa, Date of authorisation: 17/06/2024, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Ofev, nintedanib, Date of authorisation: 14/01/2015, Revision: 30, Status: Authorised

New Approach Methodologies Operational Expert Group

Committee for Medicinal Products for Human Use (CHMP): 12-15 October 2026, European Medicines Agency, Amsterdam, the Netherlands, from 12 October 2026 to 15 October 2026

Annex to agenda of the CHMP meeting 12-15 October 2026

Agenda of the CHMP meeting 12-15 October 2026

Women's health

Human medicines European public assessment report (EPAR): Sunitinib Accord, sunitinib, Date of authorisation: 11/02/2021, Revision: 5, Status: Authorised